newsfilter
← Latest News
Business Wire·

PureTech Announces Annual Results for Year Ended December 31, 2025

Refined strategy and disciplined execution position Company to unlock value from its portfolio, which includes Celea Therapeutics' Phase 3-ready deupirfenidone for idiopathic pulmonary fibrosis, Gallop Oncology's